Major purchase option for a larger pharmaceutical company. Over the past year this company has stabalized itself significantly. FOLOTYN already has approval through the FDA for use in some cancers, and its market will only grow as the drug gains… More
Let's face facts. Folotyn just hasn't worked out the way Allos longs hoped it would. I was optimistic and green-thumbed - oops. And now the share price has been creeping up for the last month after bottoming at 1.25. But I'm not seeing Folotyn ever… More